San Francisco, CANCT07214467Now EnrollingIRB Ready

Substance Use Disorder (SUD) Clinical Trial in San Francisco, CA

Access cutting-edge substance use disorder (sud) treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by University of California, San Francisco

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access substance use disorder (sud) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related substance use disorder (sud) treatment provided free

Apply for This San Francisco Location

Check if you qualify for this substance use disorder (sud) clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Substance Use Disorder (SUD) Study in San Francisco

The purpose of this study is to determine if personalized (adaptive) Deep Brain Stimulation (DBS) based upon invasive brain mapping is safe and can lead to better outcomes like reductions in craving and opioid use.

Sponsor: University of California, San Francisco

Who Can Participate

Inclusion Criteria

Adults (all genders) 22 to 75 years old.
Current diagnosis of severe primary opioid use disorder (OUD) (\>= 6 on DSM-5 OUD criteria) (any form of opioid use).
History of opioid use for more than 5 years.
Participants are seeking treatment for their OUD.
Participants have insight into their opioid use disorder (score \> 26 on the recognition subscale of the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES V.8))
OUD is treatment refractory: unable to achieve sustained remission over the past 5 years, despite at least three treatment attempts (outpatient, residential, inpatient), with at least one treatment attempt involving taking a first-line medication for OUD (MOUD) such as buprenorphine, methadone, or extended-release naltrexone. Treatment failure is defined as continued opioid use or relapse during or after completion of treatment. Sustained remission is defined per DSM-5 as not meeting any OUD criteria except craving for \> 12 months. Documented adherence: participants must have documented adherence to the failed first-line MOUD for at least 8 weeks (PMID: 29083570).
Stated willingness to comply with all study procedures and availability for the duration of the study.
Social support system and stable living arrangement to provide assurances that the subject will adhere to study requirements: family or friends who live with or near the subject, and can provide collateral information, monitor the subject's behavior, support, and encourage the subject to participate in follow-up visits and evaluations.
For individuals of reproductive potential: use of highly effective contraception for at least 4 weeks prior to sEEG surgery and agreement to use such a method during study participation.

Exclusion Criteria

Pregnancy or lactation.
Non-English speaking.
Participants are not willing to start MOUD treatment with buprenorphine or to switch MOUD to buprenorphine if they are already on other MOUD, for the duration of the study.
OUD treatment with another investigational drug or other intervention within 3 months.
History of primary psychosis or Bipolar I disorder per the medical interview.
History of severe personality disorder that could interfere with study participation (e.g., antisocial personality disorder) per the medical interview.
History of traumatic brain injury with loss of consciousness greater than 5 minutes.
Clinically significant cognitive impairment per neuropsychological testing.
History of suicidal attempts in the past 3 years or current suicidal thoughts per psychiatric evaluation.
Coagulopathy: INR \> 1.4, aPTT \> 40 s, platelets \< 100,000.
Current clinically significant medical or neurologic disease that affects brain function (e.g., recent stroke, myocardial infarction, seizures not due to alcohol withdrawal).
Clinically significant abnormality on structural brain MRI scan.
Life expectancy less than 24 months per the clinical judgment of study investigators (e.g., terminal cancers).
Any labeled DBS contraindication or inability to have brain MRI: certain pacemakers, metal in body, inability to undergo awake operation, significant cardiac or other medical risk factors for surgery, infection, and coagulopathy.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT07214467) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Substance Use Disorder (SUD) Treatment Options in San Francisco, CA

If you're searching for substance use disorder (sud) treatment options in San Francisco, CA, this clinical trial (NCT07214467) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced substance use disorder (sud) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all substance use disorder (sud) clinical trials near you to find additional studies recruiting in your area.

More Substance Use Disorder Trials in San Francisco, CA

See all substance use disorder clinical trials recruiting in San Francisco — not just this study.

Browse Substance Use Disorder Trials in San Francisco →

Browse More Trials by Condition

Substance Use Disorder TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA